Evidence‑Based Management of Refractory Insomnia in Patients Receiving Buprenorphine

1. Medication Selection and Guideline Recommendations

The American Academy of Sleep Medicine (AASM) 2017 guideline recommends temazepam 15 mg as an evidence‑based option for both sleep‑onset and sleep‑maintenance insomnia; trials supporting this dose demonstrated efficacy without additional benefit at higher doses. [@1]
When first‑line non‑benzodiazepine agents (e.g., CBT‑I, orexin antagonists, ramelteon, low‑dose doxepin) have failed, the AASM acknowledges that benzodiazepine receptor agonists such as temazepam are appropriate for refractory cases. [@3][@1]
The FDA‑approved maximum adult dose of zolpidem is 10 mg; the AASM guideline is based exclusively on studies using this dose, and no evidence supports efficacy or safety of a 20 mg regimen. [@1]
The FDA has issued dose‑dependent warnings for complex sleep behaviors (e.g., sleep‑driving, sleepwalking) with zolpidem, making supratherapeutic dosing especially unsafe in patients with substance‑use histories. [@2]

Reducing temazepam from 30 mg to the guideline‑recommended 15 mg nightly minimizes adverse effects while preserving sleep‑benefit. [@1]
If sleep quality declines after the 15 mg reduction, a step‑wise titration to 22.5 mg (rather than returning to 30 mg) is supported as a compromise between efficacy and safety. [@1]

Adding low‑dose doxepin (3–6 mg) to temazepam 15 mg targets sleep‑maintenance disturbances and can allow further reduction of the benzodiazepine dose over time. [@2]
The AASM explicitly recommends this temazepam + low‑dose doxepin strategy for refractory insomnia when monotherapy is insufficient. [@2]
Doxepin at 3–6 mg selectively blocks H1 receptors, improving sleep maintenance without anticholinergic effects; higher (antidepressant) doses lose this selectivity and are not advised for insomnia. [@2]

Zolpidem 20 mg is off‑label, lacks supporting evidence, and exceeds FDA dosing limits; it should not be prescribed. [@1]
Trazodone is not recommended by the AASM because it showed only a 1.38 % improvement in sleep efficiency versus placebo (95 % CI ‑2.87 to 5.63) and carries notable side effects. [@1]
Quetiapine is classified only as an “other sedating agent” for specific comorbidities and is not a guideline‑endorsed primary insomnia treatment; it also poses metabolic and mortality risks. [@2]
Mirtazapine is absent from the AASM 2017 recommendations, indicating insufficient evidence for primary insomnia. [@2]
Lorazepam 2 mg is not a guideline‑recommended benzodiazepine for insomnia; the AASM prefers triazolam 0.25 mg or temazepam 15 mg. [@1]
Diphenhydramine and other over‑the‑counter antihistamines are explicitly discouraged by the AASM due to anticholinergic adverse effects and lack of efficacy. [@2]

Implement a structured monitoring plan: monthly clinic visits, urine drug screens, pill counts, and a written treatment agreement that mandates discontinuation of temazepam if non‑prescribed sedatives are used. This approach converts benzodiazepine prescribing from “risky” to “appropriately managed.” [@2]

All facts are derived from peer‑reviewed guideline sources and regulatory warnings, with citation identifiers provided for each statement.